The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in this controlled clinical trial publication.

GH deficiency, either in children or in adults, is a clinically relevant problem.

The diagnosis is based on dynamic tests of GH secretion, which are clear cut on a group basis but highly problematic for individual diagnosis.

The controversy surrounding the diagnosis of GH deficiency reflects the absence of a gold standard dynamic test.

Who Took Part

The study group was 12 women.

By PubMed's age tags, the people studied were adults, both men and women.

Each subject was tested twice in order to serve as his own control.

Eighteen normal volunteers (12 women, 6 men) after giving informed consent.

What Was Measured

PubMed files the paper under topics including Growth Hormone, Growth Hormone-Releasing Hormone, Hormones, Oligopeptides, Pituitary Gland, Reproducibility of Results and Stimulation, Chemical.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 12 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 15 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1996 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.